This is an open-label PET/CT study to investigate the safety and clinical monitoring value of 18F-grazy-02 in patients with lymphoma or solid tumors receiving immunotherapy, including immune checkpoint inhibition and CAR-T cell therapy.
Inclusion Criteria:
Exclusion Criteria:
zhanglinyu1@pku.edu.cn+86010-82805175
The purpose of the study is to evaluate the safety and early monitoring performance of 18F-grazy-02 for immunotherapy.
68Ga-grazytracer PET/CT of Tumor Responses to Immunotherapy
The Application of 18F-G1 PET/CT Targeting Granzyme B in the Pan-cancer Immunotherapy
Granzyme B-targeted PET Imaging Monitoring Tumor Responses to Immunotherapy
PET Imaging Study of 64Cu-GRIP B for Patients Receiving CD19-directed CAR-T Therapy
68Ga-grazytracer PET Assists in Diagnosing Pseudoprogression Following Immunotherapy in Lung Cancer.
Granzyme B PET Imaging Drug as a Predictor of Immunotherapy Response to Checkpoint Inhibitors
Early Clinical Evaluation of 18F-LY3546117 in Tumor Imaging
The Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Pancreatic Cancer.